SignatureFD’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $799K | Buy |
9,981
+2,276
| +30% | +$188K | 0.01% | 457 |
|
|
2025
Q4 | $657K | Buy |
7,705
+69
| +0.9% | +$5.66K | 0.01% | 504 |
|
|
2025
Q3 | $594K | Buy |
7,636
+152
| +2% | +$11.9K | 0.01% | 536 |
|
|
2025
Q2 | $585K | Buy |
7,484
+1,282
| +21% | +$95.6K | 0.01% | 518 |
|
|
2025
Q1 | $450K | Buy |
6,202
+638
| +11% | +$45.7K | 0.01% | 564 |
|
|
2024
Q4 | $412K | Sell |
5,564
-136
| -2% | -$9.52K | 0.01% | 592 |
|
|
2024
Q3 | $376K | Sell |
5,700
-2,010
| -26% | -$146K | 0.01% | 612 |
|
|
2024
Q2 | $712K | Buy |
7,710
+276
| +4% | +$24.4K | 0.01% | 393 |
|
|
2024
Q1 | $710K | Buy |
7,434
+749
| +11% | +$62.9K | 0.02% | 411 |
|
|
2023
Q4 | $510K | Sell |
6,685
-1,652
| -20% | -$115K | 0.01% | 467 |
|
|
2023
Q3 | $578K | Sell |
8,337
-1,756
| -17% | -$141K | 0.02% | 397 |
|
|
2023
Q2 | $952K | Buy |
10,093
+354
| +4% | +$30.8K | 0.02% | 259 |
|
|
2023
Q1 | $806K | Buy |
9,739
+2,014
| +26% | +$158K | 0.02% | 294 |
|
|
2022
Q4 | $576K | Sell |
7,725
-1,518
| -16% | -$117K | 0.02% | 373 |
|
|
2022
Q3 | $764K | Sell |
9,243
-225
| -2% | -$21.6K | 0.03% | 250 |
|
|
2022
Q2 | $900K | Buy |
9,468
+1,196
| +14% | +$124K | 0.03% | 213 |
|
|
2022
Q1 | $974K | Buy |
8,272
+540
| +7% | +$60.6K | 0.03% | 217 |
|
|
2021
Q4 | $1M | Buy |
7,732
+633
| +9% | +$73.8K | 0.03% | 216 |
|
|
2021
Q3 | $804K | Buy |
7,099
+482
| +7% | +$55K | 0.03% | 237 |
|
|
2021
Q2 | $685K | Buy |
6,617
+366
| +6% | +$34.5K | 0.03% | 266 |
|
|
2021
Q1 | $523K | Sell |
6,251
-50
| -0.8% | -$4.23K | 0.02% | 298 |
|
|
2020
Q4 | $575K | Buy |
6,301
+92
| +1% | +$7.63K | 0.03% | 234 |
|
|
2020
Q3 | $496K | Buy |
6,209
+1,772
| +40% | +$138K | 0.03% | 238 |
|
|
2020
Q2 | $307K | Sell |
4,437
-615
| -12% | -$43.7K | 0.02% | 328 |
|
|
2020
Q1 | $318K | Buy |
5,052
+1,077
| +27% | +$77.7K | 0.03% | 272 |
|
|
2019
Q4 | $309K | Buy |
3,975
+213
| +6% | +$16.6K | 0.02% | 351 |
|
|
2019
Q3 | $276K | Buy |
3,762
+366
| +11% | +$25.7K | 0.02% | 330 |
|
|
2019
Q2 | $209K | Sell |
3,396
-111
| -3% | -$6.71K | 0.02% | 378 |
|
|
2019
Q1 | $224K | Buy |
3,507
+297
| +9% | +$16.9K | 0.02% | 365 |
|
|
2018
Q4 | $164K | Buy |
3,210
+849
| +36% | +$43K | 0.02% | 422 |
|
|
2018
Q3 | $137K | Sell |
2,361
-114
| -5% | -$5.58K | 0.01% | 526 |
|
|
2018
Q2 | $120K | Buy |
2,475
+987
| +66% | +$46.1K | 0.01% | 557 |
|
|
2018
Q1 | $69K | Buy |
+1,488
| New | +$64.6K | 0.01% | 641 |
|
|
2016
Q4 | – | Sell |
-969
| Closed | -$39K | – | 548 |
|
|
2016
Q3 | $39K | Buy |
969
+702
| +263% | +$26.4K | 0.01% | 595 |
|
|
2016
Q2 | $9K | Buy |
267
+12
| +5% | +$411 | ﹤0.01% | 928 |
|
|
2016
Q1 | $7K | Buy |
255
+135
| +113% | +$3.73K | ﹤0.01% | 918 |
|
|
2015
Q4 | $3K | Hold |
120
| – | – | ﹤0.01% | 1003 |
|
|
2015
Q3 | $3K | Buy |
+120
| New | +$2.9K | ﹤0.01% | 937 |
|
|
2015
Q2 | – | Sell |
-54
| Closed | -$1K | – | 1086 |
|
|
2015
Q1 | $1K | Buy |
+54
| New | +$1.21K | ﹤0.01% | 872 |
|
Other funds holding EW
VCM
VPM
SignatureFD's EW Position: Q1 2026 in Review
SignatureFD increased its Edwards Lifesciences (EW) stake by 30% in Q1 2026, buying an estimated $188K and bringing the position to 9,981 shares worth $799K. The position accounts for 0.01% of the portfolio, ranked #457.
SignatureFD first reported a position in EW in Q1 2015 and has held it in 39 quarters since. The position peaked at $1M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- SignatureFD held 9,981 shares of Edwards Lifesciences worth $799K as of Q1 2026.
- SignatureFD bought 2,276 Edwards Lifesciences shares in Q1 2026, an estimated $188K.
- Edwards Lifesciences made up 0.01% of SignatureFD's portfolio in Q1 2026, its #457 holding.
- SignatureFD first reported a position in Edwards Lifesciences in Q1 2015 and has held it in 39 quarters since.
- SignatureFD's Edwards Lifesciences position peaked at $1M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.